Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bruce Montgomery

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Cancer|July 20, 2007
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancerR Bruce Montgomery, Peter S Nelson, Daniel Lin, et al.
JAMA Network Open|March 12, 2024
Survival in Patients With De Novo Metastatic Prostate CancerMartin W Schoen, R Bruce Montgomery, Lukas Owens, et al.
The Prostate|June 1, 2005
Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cellsR Bruce Montgomery, Michael Bonham, Peter S Nelson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2007
Do statins affect androgen levels in men? Results from the Boston area community health surveySusan A Hall, Stephanie T Page, Thomas G Travison, et al.
Cancer Research|November 26, 2009
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progressionDiping Wang, R Bruce Montgomery, Lucy J Schmidt, et al.
Medical Oncology (Northwood, London, England)|June 15, 2016
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Elahe A Mostaghel, et al.
The Journal of Urology|September 18, 2007
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916R Bruce Montgomery, Bryan Goldman, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumorsJennifer D Wu, Kathy Haugk, Ilsa Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancerStephen R Plymate, Kathy Haugk, Ilsa Coleman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 27, 2011
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomesJonathan L Wright, Erika M Kwon, Elaine A Ostrander, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Cancer|July 20, 2007
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancerR Bruce Montgomery, Peter S Nelson, Daniel Lin, et al.
JAMA Network Open|March 12, 2024
Survival in Patients With De Novo Metastatic Prostate CancerMartin W Schoen, R Bruce Montgomery, Lukas Owens, et al.
The Prostate|June 1, 2005
Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cellsR Bruce Montgomery, Michael Bonham, Peter S Nelson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2007
Do statins affect androgen levels in men? Results from the Boston area community health surveySusan A Hall, Stephanie T Page, Thomas G Travison, et al.
Cancer Research|November 26, 2009
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progressionDiping Wang, R Bruce Montgomery, Lucy J Schmidt, et al.
Medical Oncology (Northwood, London, England)|June 15, 2016
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Elahe A Mostaghel, et al.
The Journal of Urology|September 18, 2007
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916R Bruce Montgomery, Bryan Goldman, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumorsJennifer D Wu, Kathy Haugk, Ilsa Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancerStephen R Plymate, Kathy Haugk, Ilsa Coleman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 27, 2011
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomesJonathan L Wright, Erika M Kwon, Elaine A Ostrander, et al.
Pageof 5